The MHRA (Medicines and Healthcare Products Regulatory Agency) has granted marketing authorisation for ofatumumab (Kesimpta) to treat relapsing remitting multiple sclerosis where people are having relapses or showing new lesions on MRI scans.
We are very pleased that ofatumumab has been granted a UK licence. Ofatumumab is an effective treatment which people take at home once a month and will be a useful alternative to other disease modifying drugs which require treatment in hospital clinics.
- David Martin, Chief Executive Officer, MS Trust
Ofatumumab will now need to be appraised by NICE and SMC to decide if it should be prescribed by the NHS in the UK. NICE has started the process and a decision is expected to be published before the end of April. SMC has also begun their appraisal with a decision expected later this year.
Ofatumumab is self-injected under the skin. The first three injections are taken weekly, followed by injections once a month.
In clinical trials for relapsing MS, ofatumumab reduced the risk of relapse by 50-59% compared to Aubagio, reduced disability progression and the number of lesions seen on MRI scans.
Ofatumumab is a monoclonal antibody, a type of drug developed to attack specific targets in the immune system. Ofatumumab binds to a marker (CD20) on the surface of B cells, a type of white blood cell (lymphocyte) which is thought to be involved when the immune system attacks the myelin coating of nerves. Targeted B cells are destroyed. Ofatumumab works in similar way to Ocrevus (ocrelizumab.
In clinical trials, the most frequent side effects were injection related reactions. Most of these were mild to moderate, cleared up the same or following day and were associated with the first ofatumumab injection; they were less frequent with subsequent injections. Other side effects that occurred in at least 10% of those taking ofatumumab were head colds, headache, chest infections and urinary tract infections.
Kesimpta (ofatumumab) approved for relapsing remitting MS in Scotland
12 Jul 2021 - 00:00
The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.
Stem cell transplants in the news
5 Jul 2021 - 00:00
Difficulties accessing NHS stem cell transplants (also known as HSCT or AHSCT) for multiple sclerosis were highlighted in national newspapers this weekend.
MS onset in childhood: do disease modifying drugs delay long term disability?
17 Jun 2021 - 00:00
Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.